An expert roundtable of headache specialists helps outline chronic migraine as its own entity, disparities and barriers to treatment, and a need for better research and education.
In a systematic review and meta-analysis, researchers sought to compare outcomes associated with the use of lasmiditan, rimegepant, and ubrogepant vs triptans for the acute management of migraine headaches.
Individuals without a migraine history have increased odds of achieving CMH, although the association is attenuated after adjustment for physical health and mental health problems.
